Navigation Links
New Data Show CIMZIA(R) (certolizumab pegol) Provides Sustained and Significant Symptom Improvement in Moderate to Severe Crohn's Patients
Date:10/26/2009

erapy in patients with chronic or recurrent infection. Patients should be closely monitored for the development of signs and symptoms of infection during and after treatment with CIMZIA, including the possible development of tuberculosis in patients who tested negative for latent tuberculosis infection prior to initiating therapy.

Serious and sometimes fatal infection due to bacterial, mycobacterial, invasive fungal, viral or other opportunistic pathogens has been reported in patients receiving TNF-blocking agents. Among opportunistic infections, tuberculosis, histoplasmosis, aspergillosis, candidiasis, coccidioidomycosis, listeriosis, and pneumocystosis were the most common. Treatment with CIMZIA should not be initiated in patients with an active infection, including clinically important localized infections. CIMZIA should be discontinued if a patient develops a serious infection or sepsis. Patients who develop a new infection during treatment with CIMZIA should be closely monitored, undergo a prompt and complete diagnostic workup appropriate for immunocompromised patients, and appropriate antimicrobial therapy should be initiated. Appropriate empiric antifungal therapy should also be considered while a diagnostic workup is performed for patients who develop a serious systemic illness and reside or travel in regions where mycoses are endemic.

Malignancies

During controlled and open-labeled portions of CIMZIA studies of Crohn's disease and other diseases , malignancies (excluding non-melanoma skin cancer) were observed at a rate of 0.5 per 100 patient-years among 4,650 CIMZIA-treated patients versus a rate of 0.6 per 100 patient-years among 1,319 placebo-treated patients. In studies of CIMZIA for Crohn's disease and other investigational uses, there was one case of lymphoma among 2,657 CIMZIA-treated patients and one case of Hodgkin lymphoma among 1,319 placebo-treated patients. In CIMZIA RA clinical trials (placebo-
'/>"/>

SOURCE UCB
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine technology :

1. CIMZIA(R) (Certolizumab Pegol) Provides Rapid and Sustained Relief from Signs and Symptoms of Rheumatoid Arthritis for Two Years
2. CIMZIA(R) (Certolizumab Pegol) Provides Long-Term Benefit Without Dose Escalation in Crohns Disease Patients
3. CIMZIA(R) (certolizumab pegol) Reduces Intestinal Lesions and Induces Endoscopic Improvement in Crohns Patients
4. Cimzia(R) Provides Long-Term Efficacy with Stable Dosing in Crohns Disease
5. CIMZIA(R) (certolizumab pegol), Significantly Reduces Structural Damage and Rheumatoid Arthritis Signs & Symptoms for Up to One Year
6. e-Zassi.com Provides Industry With Online U.S. FDA Regulatory Calculator for Rapid Medical Device Technology Assessment
7. Access Pharmaceuticals Provides Update on MuGard Commercial Launch and First European Clinicians Feedback
8. New ALS Patient Simulator Advanced Provides Valuable Training for EMS Teams and In-Hospital Emergency Personnel
9. CardioGenics Holdings Inc. Provides Update on FINRA Submission Regarding Name Change
10. Young Innovations, Inc. Provides Third Quarter Conference Call Details
11. Helix BioPharma Provides Updates on Topical Interferon Alpha-2b and L-DOS47 Following Pre-IND Meetings With the U.S. FDA
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... 2014 In today,s rapidly changing, highly ... tools are essential for survival. The world is ... desires, preferences, and unmet needs are evolving rapidly. ... across all industries are continually searching for innovative ... adoption of new market research techniques like mobile ...
(Date:12/19/2014)... CARDIFF-BY-THE-SEA, Calif. , Dec. 19, ... SRNE ;  Sorrento), an oncology company developing new ... Inc., a privately-held immuno-oncology company developing proprietary Neukoplast ... based therapy, announced today that the companies have ... next generation CAR-TNK™ (pronounced as "Car-Tank") immunotherapies for ...
(Date:12/19/2014)... YORK , Dec. 18, 2014 Somewhere ... addressing hearing health was forgotten. But Audicus , ... to hear better this new year. Hearing ... facing the aging population, though it is often unaddressed. ... in four has a hearing aid, mainly due to ...
Breaking Medicine Technology:Study Uncovers New Tools and Techniques for Understanding Consumer Decision Making 2Sorrento and Conkwest Announce Exclusive Global Collaboration 2Sorrento and Conkwest Announce Exclusive Global Collaboration 3Sorrento and Conkwest Announce Exclusive Global Collaboration 4Sorrento and Conkwest Announce Exclusive Global Collaboration 5Audicus Will Help People Resolve to Hear Better in 2015 2
... , Feb. 16 Aton Pharma, Inc., ... Wayne S. Mulcahy , Ph.D., has joined the company ... of Princeton Pharma Holdings LLC, Aton is focused on ... and orphan diseases. , The company,s comprehensive portfolio ...
... , KINGWOOD, Texas , Feb. 16 ... www.imaiinc.com announced today that the company has ... interest in Assured Pharmacy, Inc. (Pink Sheets: APHY.PK) ... on selling prescription medications in the chronic pain management ...
Cached Medicine Technology:Aton Pharma Appoints Dr. Wayne Mulcahy to Vice President, Clinical Operations 2International Merchant Advisors, Inc. Signs LOI to Invest in Pharmaceutical Chain 2International Merchant Advisors, Inc. Signs LOI to Invest in Pharmaceutical Chain 3
(Date:12/22/2014)... 2014 Explorys, the leader in big ... leadership team: Greg Yarrington as Vice President of Operations, ... Wells as Vice President of Solutions. These new leaders ... jobs in 2015 to support client demand for the ... offerings, and growth of its partner network. , ...
(Date:12/22/2014)... 2014 Pasadena sleep apnea ... sleep apnea. Drowsy drivers are 15 times more likely ... well-rested, and some experts believe that sleep-deprived drivers may ... drivers. Unfortunately, millions of Americans may be sleep-deprived without ... Sleep Medicine, about 18 million Americans have sleep apnea, ...
(Date:12/22/2014)... (PRWEB) December 22, 2014 Christmas is days ... has a fast and easy solution that will please: the ... can be purchased from from $25 up to $350," says ... 100% customer satisfaction and a wide array of skin care ... fees and no expiration dates. , Gift delivery past ...
(Date:12/22/2014)... Washington, DC (PRWEB) December 22, 2014 ... Nursing Leadership Conference, next month in San ... strategies to address dynamics that often stand in ... authority, and competition. , This premier faculty ... Center for Transformational Leadership, whose mission is to ...
(Date:12/21/2014)... 2014 BellasDress.com offers a wide range ... Today, it announces its BellasDress Christmas Sale , ... online store. , BellasDress is a famous online supplier ... fans through a series of promotions. The dress experts ... , “We are proud of offering high quality ...
Breaking Medicine News(10 mins):Health News:Explorys Continues to Experience Rapid Growth, Adds Three Healthcare IT Executives to Its Leadership Team 2Health News:Explorys Continues to Experience Rapid Growth, Adds Three Healthcare IT Executives to Its Leadership Team 3Health News:Pasadena Dentist, Dr. Marine Martirosyan, Now Offers Consultations for Sleep Apnea 2Health News:2015 NLN Leadership Conference February 5-7 San Antonio 2Health News:2015 NLN Leadership Conference February 5-7 San Antonio 3Health News:BellasDress.com Announces its BellasDress Christmas Sale 2
... LYMAN, S.C., Sept. 11 Southern Home Medical,Equipment, Inc. ... the month of August 2008 compared to July 2008., ... stated, "On the heels of,reporting record sales in the ... on a path of strong sales momentum. Encore Medical ...
... against women in a family also has serious consequences ... sling Monemi from Uppsala University has studied women and ... other things, that children whose mothers are exposed to ... other children. , Kajsa sling Monemi, paediatrician, the ...
... - For Non-US Healthcare Media, - Global ... Improved Survival Outcomes With Vetmedin(R) (pimobendan), Veterinarians and ... promise of an extended happy life together for millions ... that dogs,suffering from the most common type of heart ...
... Residents to Eat Right, Move More ... and Milk Their Diets, BOSTON, Sept. 11 ... fad diets -- which seem to go in and out of,fashion like shoulder ... -- including 51 percent of Massachusetts,residents -- remain overweight or obese., A ...
... 11 Oculus Innovative,Sciences, Inc. (Nasdaq: OCLS ), ... of products based upon the Microcyn(R),Technology platform, today announced ... exclusive interview on WallSt.net,s 3-Minute Press Show., The ... the,significance of the company,s latest press release., ...
... Plastic surgeon offers the surprise scoop, NEW ... time and an,active lifestyle can impact a person,s ... million Americans turned to cosmetic procedures last,year to ... Shirley Madhere, M.D., says you can improve your ...
Cached Medicine News:Health News:Southern Home Medical Announces Revenues Up 172% for the Month of August 2Health News:Landmark Research Heralds New Era in Dog Heart Treatment and Longer Life for Dogs 2Health News:Landmark Research Heralds New Era in Dog Heart Treatment and Longer Life for Dogs 3Health News:Landmark Research Heralds New Era in Dog Heart Treatment and Longer Life for Dogs 4Health News:Message to Boston Residents: Forgo Fad Dieting and Join the Campaign for Healthy Weight 2Health News:Message to Boston Residents: Forgo Fad Dieting and Join the Campaign for Healthy Weight 3Health News:Message to Boston Residents: Forgo Fad Dieting and Join the Campaign for Healthy Weight 4Health News:[video] Hojabr Alimi, CEO of Oculus Innovative Sciences, Inc. Discusses Reduction of Planned Expenses on WallSt.net's 3-Minute Press Show 2Health News:Insider Secrets for Beautiful Skin 2
... RELISA ENA Multiparameter Kit is ... for six of the most ... a unique quality control system. ... Check) well in each strip ...
... RELISA ENA assays were designed with the ... clinician in the diagnosis of autoimmune disease. ... disease and 1,000 normal individuals were tested ... Test System. Immuno Concepts compared the results ...
... functional human C1q coated in the solid phase ... stage, CIC in the diluted patient samples and ... into the C1q coated assay wells. After incubation, ... and a ready to use conjugate (goat anti-human ...
... CIC are formed as a host ... cleared by phagocytosis. If not cleared, CIC ... inflammatory response. CIC are increased in Systemic ... may be involved in other autoimmune disorders ...
Medicine Products: